Powder: -20°C for 3 years | In solvent: -80°C for 1 year
UC2288 is a relatively selective p21 attenuator which is synthesized based Sorafenib. UC2288 attenuates p21 protein levels with minimal effect on p21 protein stability.
説明 | UC2288 is a relatively selective p21 attenuator which is synthesized based Sorafenib. UC2288 attenuates p21 protein levels with minimal effect on p21 protein stability. |
In vitro | UC2288 (0-10 μM; 24 hours) decreases p21 mRNA expression transcriptionally or post-transcriptionally but independently of p53. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM[1]. |
In vivo | UC2288 (10 mg/kg; i.p.) attenuates MPTP-induced behavioral impairment, prevents activation of MAPK pathway in the MPTP-treated mice brain. MPTP treatment raises TNF-α, IL-6 and IL-1β levels in MPTP treated mice brain, but UC2288 signicantly decreases MPTP-induced TNF-α, IL-6 levels, but IL-1β is not decreased in brain[2].UC2888 (15 mg/kg; oral) co-treatment with imetelstat significantly suppresses tumor growth and does not effect mice weight[3]. |
分子量 | 481.82 |
分子式 | C20H18ClF6N3O2 |
CAS No. | 1394011-91-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 48 mg/mL (99.62 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
UC2288 1394011-91-6 Apoptosis Mdm2 p53 Attenuator 786-O Inhibitor MDM-2/p53 UC 2288 inhibit ovarian RCC HK2 p21 sorafenib UC-2288 p53-mutant cancer inhibitor